Insulin aspart - Biologic Drug Details

✉ Email this page to a colleague

▶ Start for $1
Remove trial restrictions

Summary for insulin aspart

Tradenames:	2
Patents:	18
Applicants:	1
BLAs:	4
Suppliers: see list	4
Recent Clinical Trials:	See clinical trials for insulin aspart
Drug Prices:	Drug price information for insulin aspart
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for insulin aspart

Recent Clinical Trials for insulin aspart

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Amphastar Pharmaceuticals, Inc.	Phase 2/Phase 3
Defymed	N/A
McGill University Health Centre/Research Institute of the McGill University Health Centre	N/A

See all insulin aspart clinical trials

Recent Litigation for insulin aspart

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Novo Nordisk Inc. v. Alvogen, Inc.	2022-03-03
Novo Nordisk Inc. v. Zydus Worldwide DMCC	2022-03-03
Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc.	2022-03-03

See all insulin aspart litigation

Pharmacology for insulin aspart

Established Pharmacologic Class	Insulin Analog
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin aspart Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin aspart Derived from Company Disclosures

These patents were obtained from company disclosures

Glossary

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986	See Plans and Pricing	2014-04-08	Company disclosures
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986	See Plans and Pricing	2014-05-06	Company disclosures
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986	See Plans and Pricing	2014-12-02	Company disclosures
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Patent No.	>Estimated Patent Expiration	>Source

3) Low Certainty: US Patents for insulin aspart Derived from Patent Text Search

These patents were obtained by searching patent claims